Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 450 Stomach Neoplasms 295 Rectal Neoplasms 271 Colonic Neoplasms 192 Pancreatic Neoplasms 177 Neoplasm Metastasis 110 Esophageal Neoplasms 88 Neoplasms 68 Carcinoma, Hepatocellular 60 Adenocarcinoma Of Esophagus 47 Cholangiocarcinoma 46 Adenocarcinoma 46 Lymphoma, Large B-Cell, Diffuse 44 Carcinoma, Non-Small-Cell Lung 41 Biliary Tract Neoplasms 38 Gallbladder Neoplasms 31 Gastrointestinal Neoplasms 29 Recurrence 25 Liver Neoplasms 25 Ovarian Neoplasms 23 Esophageal Squamous Cell Carcinoma 23 Breast Neoplasms 22 Peritoneal Neoplasms 18 Bile Duct Neoplasms 17 Unspecified Adult Solid Tumor, Protocol Specific 16 Parkinson Disease 4, Autosomal Dominant Lewy Body 14 Locally Advanced Rectal Cancer 13 Head and Neck Neoplasms 13 Lung Neoplasms 12 Lymphoma, Non-Hodgkin 11

Interventions

Radiotherapy 4 Immune Checkpoint Inhibitors 4 famitinib 1 camrelizumab 1 aflutinib 1 Oxaliplatin 1 Nivolumab 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced NSCLC × Oxaliplatin × Clear all

NCT04043195 2025-05-28

NSCLC

University of California, San Diego

Phase 1/2 Active not recruiting

Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡